Abstract 6274: Preclinical characterization of the BET inhibitor, INCB057643, in combination with ruxolitinib for treatment of myeloproliferative neoplasms (MPN)Michelle Pusey, Sunkyu Kim, Bob Collins et al.|Cancer Research|2023Cited by 2